GENERAL DERMATOLOGY

High prevalence of alcohol use disorders in patients with inflammatory skin diseases

Plain Language Summary available

Article first published online: 07 Jul 2017
DOI: 10.1111/bjd.15497

Comment on this article

Summary

Background

There is a known association between psoriasis and heavy alcohol consumption. The association between heavy alcohol consumption and other inflammatory skin diseases remains to be defined.

Objectives

To examine the prevalence of heavy drinking using the Alcohol Use Disorders Identification Test ( AUDIT ) in patients with inflammatory skin disease.

Methods

We conducted an observational cross‐sectional study in a single hospital outpatient department. We recruited 609 patients with either psoriasis, eczema, cutaneous lupus or other inflammatory disorders, and a reference population with skin lesions. Primary outcome was the proportion of patients in each group with an alcohol use disorder ( AUD ).

Results

The observed prevalence of AUD was 30·6% in patients with psoriasis, 33·3% in those with eczema, 12·3% in those with cutaneous lupus, 21·8% in those with other inflammatory disease and 14·3% in those with non‐inflammatory disease. Odds ratios ( OR ) for AUD in patients in the inflammatory groups compared with those in the noninflammatory groups, adjusted for age and sex, were as follows: psoriasis 1·65 [95% confidence interval ( CI ) 0·86–3·17], eczema 2·00 (95% CI 1·03–3·85), lupus 1·03 (95% CI 0·39–2·71), other inflammatory disease 1·32 (95% CI 0·68–2·56). OR s were reduced if also adjusted for Dermatology Life Quality Index ( DLQI ). The prevalence of DLQI ≥ 11 was 31·1% for psoriasis, 43·7% for eczema, 17·5% for cutaneous lupus, 17·2% for other inflammatory disease and 2·8% for noninflammatory disease.

Conclusions

Patients with eczema attending a hospital clinic have been shown to have high levels of AUD of a similar level to patients with psoriasis and higher than patients with noninflammatory skin diseases.

Read moreRead more (PDF)

Share this article

0

Favourite

Comments

If you want to submit a letter for publication rather than comment on an article please submit through Scholar One: https://mc.manuscriptcentral.com/bjd

There are no comments for this article yet.

Recent Tweets

@BrJDermatol

05 Dec 2019

RT The British Association of Dermatologists @HealthySkin4All: The authors of this @BrJDermatol study have described factors which could help doctors to identify children with eczema at a higher risk of eczema continuing into adulthood. https://t.co/ZNNzE7iZ4h @eczemasociety @eczemasupport @EczemaOutreach @Wiley_Health https://t.co/2ADGsWtDAY

@BrJDermatol

04 Dec 2019

The December issue of @BrJDermatol is out now! https://t.co/5k5nitO7lx https://t.co/XeGa1M69uC

@BrJDermatol

04 Dec 2019

RT The British Association of Dermatologists @HealthySkin4All: You can stay up to date with all the latest research from the @BrJDermatol by reading the free plain language summaries of research online here: https://t.co/SY2AkPpw61 https://t.co/gaNkextAJj

@BrJDermatol

04 Dec 2019

In #psoriasis how does the #microbiome differ in #lesional skin compared to normal skin and controls? Results from standard culture and 16S RNA sequencing: https://t.co/5IvWYjltcn https://t.co/abvf9cbvUl

@BrJDermatol

03 Dec 2019

Watch this video about developing and validating the PP-NRS (Peak Pruritus Numerical Rating Scale), a psychometric test for assessing the intensity of #itch in patients with #AtopicDermatitis : https://t.co/c0UXDaxeC6

@BrJDermatol

03 Dec 2019

RT EPI-PHARE @EPIPHARE: Des membres d'EPI-PHARE ont publié un article dans British Journal of Dermatology [EN] New article from EPI-PHARE members in @BrJDermatol ➡️ Persistence of treatment with conventional systemic agents for patients with #psoriasis... 🔗 https://t.co/WKcPUhs4Io https://t.co/0GDaE7byHy

Close